Nuvalent, INC Form 4 insider transactions

Nuvalent, Inc. reports that Chief Development Officer Darlene Noci sold shares of Class A Common Stock as part of a pre-arranged trading plan.

Nuvalent, Inc. reports insider transactions involving Class A Common Stock, including sales executed under a Rule 10b5-1 trading plan.

Nuvalent, Inc. President and CEO James Richard Porter sold 30,000 shares of Class A Common Stock for $18.93 per share, and an additional 21,597 shares in multiple transactions at weighted average prices ranging from $98.28 to $103.05, all executed on May 4, 2026, under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Financial Officer, Alexandra Balcom, executed trades involving Class A Common Stock and stock options on May 1, 2026, under a pre-established Rule 10b5-1 trading plan.

Nuvalent Chief Legal Officer Deborah Ann Miller exercised options and sold 5,500 shares of Class A Common Stock.

Nuvalent, Inc. Chief Development Officer Darlene Noci exercised options and sold 5,500 shares of Class A Common Stock under a 10b5-1 plan.

Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reports transactions involving Class A Common Stock, including sales executed under a Rule 10b5-1 trading plan.

Nuvalent, Inc. President and CEO James Richard Porter executed a series of stock transactions on April 6, 2026, under a pre-established Rule 10b5-1 trading plan.

Nuvalent's Chief Financial Officer, Alexandra Balcom, has executed a Rule 10b5-1 trading plan, resulting in the sale of company stock and the acquisition of stock options.

Nuvalent, Inc. Chief Technical Operations Officer Benjamin Lane was granted 9,500 restricted stock units and 19,000 stock options.

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold a portion of her Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Chief Legal Officer Deborah Ann Miller exercised options and sold 5,500 Nuvalent shares on March 26, 2026 under a Rule 10b5-1 plan.

Nuvalent's Chief Scientific Officer, Henry E. Pelish, executed pre-planned stock option exercises and subsequent sales of Class A Common Stock.

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold an equivalent number of Class A Common Stock shares.

Nuvalent's Chief Legal Officer, Deborah Ann Miller, exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Legal Officer, Deborah Ann Miller, exercised stock options and subsequently sold Class A Common Stock totaling 15,000 shares in pre-planned transactions.

Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold shares to cover tax obligations and received new restricted stock units and stock options.

Nuvalent's Chief Development Officer, Darlene Noci, reported sales of Class A Common Stock to cover tax obligations and the acquisition of new restricted stock units and stock options.

Nuvalent's Chief Legal Officer, Deborah Ann Miller, reported sales of Class A Common Stock to cover tax obligations and the acquisition of new restricted stock units and stock options.

Nuvalent's Chief Medical Officer, Christopher Durant Turner, reported sales of Class A Common Stock under a 10b5-1 plan and received new equity awards.

Nuvalent Inc.'s Chief Financial Officer, Alexandra Balcom, sold shares to cover tax obligations from vested equity awards and simultaneously received new grants of restricted stock units and stock options.

Nuvalent's President and CEO, James Richard Porter, reported sales of Class A Common Stock under a 10b5-1 plan for tax obligations, alongside the acquisition of new restricted stock units and stock options.

Nuvalent's Chief Legal Officer, Deborah Ann Miller, exercised stock options and subsequently sold 10,000 shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged trading plan.

Nuvalent's Chief Scientific Officer, Henry E. Pelish, exercised stock options to acquire 5,085 shares of Class A Common Stock.

Nuvalent's Chief Financial Officer, Alexandra Balcom, exercised 34,500 stock options at $1.08 per share, increasing her direct ownership of Class A Common Stock.

Nuvalent Inc.'s President and CEO, James Richard Porter, exercised options to acquire 57,000 shares of Class A Common Stock at $0.65 per share.

Nuvalent Director Ron Squarer was granted 2,837 restricted stock units and options to purchase 4,418 shares of Class A Common Stock, vesting over three years.

Nuvalent's Chief Financial Officer, Alexandra Balcom, sold Class A Common Stock totaling 7,084 shares on December 8, 2025, under a pre-arranged 10b5-1 trading plan.